A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount.
Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.
Journal for immunotherapy of cancer. 2021 Jul [Epub]
Matthew D Galsky, Arjun V Balar, Peter C Black, Matthew T Campbell, Gail S Dykstra, Petros Grivas, Shilpa Gupta, Christoper J Hoimes, Lidia P Lopez, Joshua J Meeks, Elizabeth R Plimack, Jonathan E Rosenberg, Neal Shore, Gary D Steinberg, Ashish M Kamat
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York, USA., Department of Urologic Sciences, The University of British Columbia, Vancouver, British Columbia, Canada., Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bladder Cancer Advocacy Network (BCAN), Bethesda, Maryland, USA., Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA., Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA., Department of Medicine, Duke Cancer Institute, Duke University, Durham, North Carolina, USA., Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA., Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA., Department of Urology and Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA., Department of Urology under Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA .